Quick Dispatch:
Your eccogene glp-1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eccogene glp-1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases ships.
Need Help?
Questions about eccogene glp-1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eccogene glp-1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases in your area.
Eccogene will present Phase 1b data for elecoglipron (AZD5004/ECC5004), our investigational oral small-molecule GLP-1 receptor agonist, in a late-breaking poster presentation at the American Diabetes…
21.92
AstraZeneca buys rights to GLP-1 drug from Eccogene for $185M upfront
20.55
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
22.04
AstraZeneca stays in GLP-1 drug race with new deal
24.65
The outlook for obesity from 2026 to 2030
22.24
AstraZeneca raises stakes in obesity drug race with Eccogene deal
22.86
Eccogene files for Hong Kong IPO to boost oral therapy pipeline | Shin-En Peng posted on the topic
22.54
![Zepbound Lawsuit [2026]](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Zepbound-Lawsuit-Severe-Digestive-Conditions-Alleged-in-GLP-1-Lawsuits-torhoerman-law.jpg)
